152 related articles for article (PubMed ID: 34870621)
1. Evaluation of Clinical Efficacy and Safety of Prolonged Treatment of Vernal and Atopic Keratoconjunctivitis Using Topical Tacrolimus.
Hirota A; Shoji J; Inada N; Shiraki Y; Yamagami S
Cornea; 2022 Jan; 41(1):23-30. PubMed ID: 34870621
[TBL] [Abstract][Full Text] [Related]
2. Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic Dermatitis.
Shoji J; Ohashi Y; Fukushima A; Miyazaki D; Uchio E; Takamura E; Fujishima H; Namba K; Kumagai N; Ebihara N; Okamoto S
Curr Eye Res; 2019 Jul; 44(7):796-805. PubMed ID: 30947551
[No Abstract] [Full Text] [Related]
3. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.
Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H
J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis.
Yazu H; Shimizu E; Aketa N; Dogru M; Okada N; Fukagawa K; Fujishima H
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):387-392.e1. PubMed ID: 30639466
[TBL] [Abstract][Full Text] [Related]
5. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.
Kheirkhah A; Zavareh MK; Farzbod F; Mahbod M; Behrouz MJ
Eye (Lond); 2011 Jul; 25(7):872-80. PubMed ID: 21475312
[TBL] [Abstract][Full Text] [Related]
6. [Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment].
Harada N; Inada N; Ishimori A; Shoji J; Sawa M
Nippon Ganka Gakkai Zasshi; 2014 Apr; 118(4):378-84. PubMed ID: 24864437
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis.
Wan Q; Tang J; Han Y; Wang D; Ye H
Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis.
Caputo R; Marziali E; de Libero C; Di Grande L; Danti G; Virgili G; Villani E; Mori F; Bacci GM; Lucenteforte E; Pucci N
Cornea; 2021 Nov; 40(11):1395-1401. PubMed ID: 34029239
[TBL] [Abstract][Full Text] [Related]
9. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis.
Tzu JH; Utine CA; Stern ME; Akpek EK
Cornea; 2012 Jun; 31(6):649-54. PubMed ID: 22378107
[TBL] [Abstract][Full Text] [Related]
10. Dermatologic tacrolimus ointment on the eyelids for steroid-refractory vernal keratoconjunctivitis.
Liu FY; Liu HY; Chu HS; Chen WL; Hu FR; Wang IJ
Graefes Arch Clin Exp Ophthalmol; 2019 May; 257(5):967-974. PubMed ID: 30852635
[TBL] [Abstract][Full Text] [Related]
11. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis.
Wakamatsu TH; Tanaka M; Satake Y; Dogru M; Fukagawa K; Igarashi A; Fujishima H
Mol Vis; 2011 Apr; 17():932-8. PubMed ID: 21541276
[TBL] [Abstract][Full Text] [Related]
12. Monotherapy of topical tacrolimus 0.03% in the treatment of vernal keratoconjunctivitis in the pediatric population.
Samyukta SK; Pawar N; Ravindran M; Allapitchai F; Rengappa R
J AAPOS; 2019 Feb; 23(1):36.e1-36.e5. PubMed ID: 30664932
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis.
Pucci N; Caputo R; Mori F; De Libero C; Di Grande L; Massai C; Bernardini R; Novembre E
Int J Immunopathol Pharmacol; 2010; 23(3):865-71. PubMed ID: 20943058
[TBL] [Abstract][Full Text] [Related]
14. Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children.
Liendo VL; Vola ME; Barreiro TP; Wakamatsu TH; Gomes JÁP; Santos MSD
Arq Bras Oftalmol; 2017; 80(4):211-214. PubMed ID: 28954018
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of 2% Rebamipide Suspension for Vernal Keratoconjunctivitis: A Clinical Comparison with Topical Immune Modulators Cyclosporine and Tacrolimus.
Malhotra C; Singh H; Jain AK; Gupta A; Ram J
Ocul Immunol Inflamm; 2022 Jul; 30(5):1083-1091. PubMed ID: 33764241
[TBL] [Abstract][Full Text] [Related]
16. Use of cyclosporine A and tacrolimus in treatment of vernal keratoconjunctivitis.
Vichyanond P; Kosrirukvongs P
Curr Allergy Asthma Rep; 2013 Jun; 13(3):308-14. PubMed ID: 23625179
[TBL] [Abstract][Full Text] [Related]
17. Role of ocular cytology in vernal keratoconjunctivitis.
Bruschi G; Ghiglioni DG; Osnaghi S; Rosazza C; Pires Marafon D; Landi M; Marchisio PG
Immun Inflamm Dis; 2020 Mar; 8(1):3-7. PubMed ID: 31804769
[TBL] [Abstract][Full Text] [Related]
18. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
Labcharoenwongs P; Jirapongsananuruk O; Visitsunthorn N; Kosrirukvongs P; Saengin P; Vichyanond P
Asian Pac J Allergy Immunol; 2012 Sep; 30(3):177-84. PubMed ID: 23156846
[TBL] [Abstract][Full Text] [Related]
19. Late-term topical tacrolimus for subepithelial infiltrates resistant to topical steroids and ciclosporin secondary to adenoviral keratoconjunctivitis.
Arici C; Mergen B
Br J Ophthalmol; 2021 May; 105(5):614-618. PubMed ID: 32563992
[TBL] [Abstract][Full Text] [Related]
20. Long-term use of topical tacrolimus ointment: a safe and effective option for the treatment of vernal keratoconjunctivitis.
Müller GG; José NK; de Castro RS; de Holanda EC
Arq Bras Oftalmol; 2019; 82(2):119-123. PubMed ID: 30698232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
